Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Long-Term Deferred Tax: 2010-2024

Historic Long-Term Deferred Tax for Anika Therapeutics (ANIK) over the last 8 years, with Dec 2024 value amounting to $1.2 million.

  • Anika Therapeutics' Long-Term Deferred Tax fell 15.01% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.01%. This contributed to the annual value of $1.2 million for FY2024, which is 20.95% down from last year.
  • Anika Therapeutics' Long-Term Deferred Tax amounted to $1.2 million in FY2024, which was down 20.95% from $1.5 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Long-Term Deferred Tax ranged from a high of $1.5 million in FY2023 and a low of $1.2 million during FY2024.
  • In the last 3 years, Anika Therapeutics' Long-Term Deferred Tax had a median value of $1.4 million in 2022 and averaged $1.4 million.
  • In the last 5 years, Anika Therapeutics' Long-Term Deferred Tax grew by 2.76% in 2023 and then declined by 20.95% in 2024.
  • Anika Therapeutics' Long-Term Deferred Tax (Yearly) stood at $1.4 million in 2022, then grew by 2.76% to $1.5 million in 2023, then fell by 20.95% to $1.2 million in 2024.